[go: up one dir, main page]

CL2016000300A1 - Métodos terapéuticos - Google Patents

Métodos terapéuticos

Info

Publication number
CL2016000300A1
CL2016000300A1 CL2016000300A CL2016000300A CL2016000300A1 CL 2016000300 A1 CL2016000300 A1 CL 2016000300A1 CL 2016000300 A CL2016000300 A CL 2016000300A CL 2016000300 A CL2016000300 A CL 2016000300A CL 2016000300 A1 CL2016000300 A1 CL 2016000300A1
Authority
CL
Chile
Prior art keywords
therapeutic methods
therapeutic agent
compound
hepatitits
hcv
Prior art date
Application number
CL2016000300A
Other languages
English (en)
Inventor
Jill Walker
Christian Voitenleitner
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000300(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CL2016000300A1 publication Critical patent/CL2016000300A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE UN COMPUESTO 2-FENIL-BENZOFURANO SUSTITUIDO Y UN SEGUNDO AGENTE TERAPEUTICO, PARA EL TRATAMIENTO DEL VIRUS DE LA HEPATITITS C (HCV); Y COMPOSICION QUE COMPRENDE A DICHO COMPUESTO Y AL SEGUNDO AGENTE TERAPEUTICO.
CL2016000300A 2011-08-17 2016-02-05 Métodos terapéuticos CL2016000300A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524429P 2011-08-17 2011-08-17
US201161526787P 2011-08-24 2011-08-24

Publications (1)

Publication Number Publication Date
CL2016000300A1 true CL2016000300A1 (es) 2016-09-02

Family

ID=47715500

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014000394A CL2014000394A1 (es) 2011-08-17 2014-02-17 Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
CL2016000300A CL2016000300A1 (es) 2011-08-17 2016-02-05 Métodos terapéuticos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2014000394A CL2014000394A1 (es) 2011-08-17 2014-02-17 Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.

Country Status (22)

Country Link
US (2) US9119868B2 (es)
EP (1) EP2744342B1 (es)
JP (2) JP6121419B2 (es)
KR (2) KR101975233B1 (es)
CN (2) CN106109479A (es)
AU (1) AU2012296446B2 (es)
BR (1) BR112014003556A2 (es)
CA (1) CA2843502C (es)
CL (2) CL2014000394A1 (es)
CO (1) CO6880064A2 (es)
CR (1) CR20140075A (es)
DO (1) DOP2014000030A (es)
EA (2) EA201690327A1 (es)
ES (1) ES2735542T3 (es)
IL (1) IL230484A (es)
MA (1) MA35347B1 (es)
MX (1) MX2014001833A (es)
PE (1) PE20141391A1 (es)
PH (1) PH12014500381A1 (es)
SG (1) SG10201606646RA (es)
WO (1) WO2013025992A1 (es)
ZA (2) ZA201400435B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101975233B1 (ko) * 2011-08-17 2019-05-07 글락소스미스클라인 엘엘씨 치료 방법
JP6367712B2 (ja) * 2011-08-19 2018-08-01 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｃ型肝炎ウイルス感染の治療のためのベンゾフラン化合物
JP2017534643A (ja) * 2014-11-10 2017-11-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｃ型肝炎のための組合せ長時間作用型組成物および方法
SG11201703645XA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Long acting pharmaceutical compositions for hepatitis c
CN105732602B (zh) * 2015-09-23 2017-04-19 常州寅盛药业有限公司 作为ns4b抑制剂的苯并呋喃类似物
JP7086987B2 (ja) * 2017-03-21 2022-06-20 ザ スクリプス リサーチ インスティテュート 銅およびニッケル触媒による脱炭酸ホウ素化反応
JP7654554B2 (ja) * 2019-10-25 2025-04-01 住友ファーマ株式会社 新規置換縮環型化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1196436A2 (en) * 1999-07-07 2002-04-17 Bristol-Myers Squibb Pharma Company Peptide boronic acid inhibitors of hepatitis c virus protease
WO2004041201A2 (en) * 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
WO2005051318A2 (en) 2003-11-24 2005-06-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
BRPI0711155A2 (pt) * 2006-05-02 2011-08-23 Anacor Pharmaceuticals Inc terapêuticos contendo boro resistentes hidroliticamente e métodos de uso
EA201000201A1 (ru) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
CA2714254A1 (en) * 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
TW201138786A (en) 2010-02-19 2011-11-16 Glaxo Group Ltd Therapeutic compounds
AU2011329485A1 (en) 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
KR101975233B1 (ko) * 2011-08-17 2019-05-07 글락소스미스클라인 엘엘씨 치료 방법
JP6367712B2 (ja) * 2011-08-19 2018-08-01 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｃ型肝炎ウイルス感染の治療のためのベンゾフラン化合物
CA2845321A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Combination treatments for hepatitis c

Also Published As

Publication number Publication date
CN103929965B (zh) 2016-08-17
ZA201400435B (en) 2015-09-30
US20150320777A1 (en) 2015-11-12
US20140212384A1 (en) 2014-07-31
KR101975233B1 (ko) 2019-05-07
US10238678B2 (en) 2019-03-26
DOP2014000030A (es) 2014-06-30
CO6880064A2 (es) 2014-02-28
PH12014500381A1 (en) 2021-07-12
JP6121419B2 (ja) 2017-04-26
EA201490199A1 (ru) 2015-01-30
CL2014000394A1 (es) 2014-08-01
ES2735542T3 (es) 2019-12-19
AU2012296446B2 (en) 2015-07-09
WO2013025992A1 (en) 2013-02-21
AU2012296446A1 (en) 2014-02-13
EP2744342B1 (en) 2019-04-24
KR20140093209A (ko) 2014-07-25
EA201690327A1 (ru) 2016-06-30
BR112014003556A2 (pt) 2017-03-21
NZ619985A (en) 2016-06-24
EP2744342A1 (en) 2014-06-25
IL230484A0 (en) 2014-03-31
EP2744342A4 (en) 2015-01-28
EA024357B1 (ru) 2016-09-30
KR20180129973A (ko) 2018-12-05
CR20140075A (es) 2014-03-24
PE20141391A1 (es) 2014-10-29
ZA201502595B (en) 2017-01-25
US9119868B2 (en) 2015-09-01
MX2014001833A (es) 2014-02-27
JP2017165732A (ja) 2017-09-21
CN103929965A (zh) 2014-07-16
SG10201606646RA (en) 2016-09-29
CA2843502A1 (en) 2013-02-21
EA201490199A8 (ru) 2015-12-30
JP2014524446A (ja) 2014-09-22
MA35347B1 (fr) 2014-08-01
CA2843502C (en) 2019-01-15
CN106109479A (zh) 2016-11-16
IL230484A (en) 2016-11-30

Similar Documents

Publication Publication Date Title
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2016000300A1 (es) Métodos terapéuticos
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000381A1 (es) Compuestos antivirales
CO6761348A2 (es) Compuestos antivirales
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2014000311A1 (es) Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio.
CL2012002057A1 (es) Compuestos macrociclicos sustituidos, como inhibidores del virus de la hepatitis c; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, utiles como agente antivirales.
CL2015000942A1 (es) Compuestos de benceno sustituido.
MX2015011473A (es) Compuesto de fosforamidato de nucleosido novedoso y su uso.
MX2019009114A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
ECSP14013315A (es) Inhibidores de aplicación viral
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
CL2010001634A1 (es) Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
MX2017009309A (es) Derivados de indol mono o disustituido como inhibidores de la replicacion del virus del dengue.
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.